Susquehanna International Group
VKTX icon

Susquehanna International Group’s Viking Therapeutics VKTX Stock Holding History

Susquehanna International Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103M Buy
3,158,000
+178,900
+6% +$5.75M 0.01% 809
2025
Q4 		$105M Buy
2,979,100
+1,003,700
+51% +$35.6M 0.01% 855
2025
Q3 		$51.9M Buy
1,975,400
+180,400
+10% +$5.38M 0.01% 1312
2025
Q2 		$47.6M Buy
1,795,000
+305,600
+21% +$8.04M 0.01% 1209
2025
Q1 		$36M Sell
1,489,400
-681,100
-31% -$21.5M 0.01% 1246
2024
Q4 		$87.3M Sell
2,170,500
-53,200
-2% -$3.03M 0.01% 802
2024
Q3 		$141M Buy
2,223,700
+85,100
+4% +$4.99M 0.02% 507
2024
Q2 		$113M Sell
2,138,600
-995,300
-32% -$65.2M 0.02% 543
2024
Q1 		$257M Buy
3,133,900
+1,984,500
+173% +$88.3M 0.04% 338
2023
Q4 		$21.4M Buy
1,149,400
+291,600
+34% +$3.81M ﹤0.01% 1747
2023
Q3 		$9.5M Sell
857,800
-886,100
-51% -$12.7M ﹤0.01% 2636
2023
Q2 		$28.3M Buy
1,743,900
+950,100
+120% +$19.9M 0.01% 1409
2023
Q1 		$13.2M Buy
793,800
+499,900
+170% +$5.16M ﹤0.01% 2122
2022
Q4 		$2.76M Buy
293,900
+220,700
+302% +$985K ﹤0.01% 4146
2022
Q3 		$199K Buy
73,200
+10,000
+16% +$32.8K ﹤0.01% 10854
2022
Q2 		$183K Buy
63,200
+6,400
+11% +$15.8K ﹤0.01% 10762
2022
Q1 		$170K Sell
56,800
-59,900
-51% -$215K ﹤0.01% 11433
2021
Q4 		$537K Sell
116,700
-233,200
-67% -$1.31M ﹤0.01% 8999
2021
Q3 		$2.2M Buy
349,900
+154,100
+79% +$952K ﹤0.01% 5621
2021
Q2 		$1.17M Sell
195,800
-169,700
-46% -$1.01M ﹤0.01% 7314
2021
Q1 		$2.31M Buy
365,500
+237,200
+185% +$1.67M ﹤0.01% 5570
2020
Q4 		$722K Sell
128,300
-163,300
-56% -$989K ﹤0.01% 7466
2020
Q3 		$1.7M Sell
291,600
-57,200
-16% -$394K ﹤0.01% 4938
2020
Q2 		$2.52M Buy
348,800
+209,300
+150% +$1.39M ﹤0.01% 4093
2020
Q1 		$653K Sell
139,500
-510,100
-79% -$3.14M ﹤0.01% 6362
2019
Q4 		$5.21M Sell
649,600
-231,600
-26% -$1.69M ﹤0.01% 2916
2019
Q3 		$6.06M Sell
881,200
-486,900
-36% -$3.62M ﹤0.01% 2484
2019
Q2 		$11.4M Buy
1,368,100
+22,600
+2% +$193K ﹤0.01% 1762
2019
Q1 		$13.4M Buy
1,345,500
+1,234,100
+1,108% +$10.3M 0.01% 1501
2018
Q4 		$852K Sell
111,400
-279,000
-71% -$3.34M ﹤0.01% 4997
2018
Q3 		$6.8M Buy
390,400
+59,700
+18% +$710K ﹤0.01% 2323
2018
Q2 		$3.14M Buy
330,700
+188,400
+132% +$1.25M ﹤0.01% 3324
2018
Q1 		$622K Buy
+142,300
New +$787K ﹤0.01% 6200

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group's VKTX Position: Q1 2026 in Review

Susquehanna International Group reduced its Viking Therapeutics (VKTX) stake by 50% in Q1 2026, selling an estimated $23.1M and leaving 705,809 shares worth $23M. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

Susquehanna International Group first reported a position in VKTX in Q3 2017 and has held it in 30 quarters since. The position peaked at $74.5M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Susquehanna International Group held 705,809 shares of Viking Therapeutics worth $23M as of Q1 2026.
  • Susquehanna International Group sold 718,022 Viking Therapeutics shares in Q1 2026, an estimated $23.1M.
  • Viking Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2060 holding.
  • Susquehanna International Group first reported a position in Viking Therapeutics in Q3 2017 and has held it in 30 quarters since.
  • Susquehanna International Group's Viking Therapeutics position peaked at $74.5M in Q2 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.